Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gradient of CD79B expression in diffuse large B-cell lymphoma corresponds to stages of germinal center B-cell differentiation.

Haematologica·2026
Same author

[Immune deficiency/dysregulation-associated lymphoma with an immunophenotype resembling EBV-positive nodal T/NK-cell lymphoma during treatment of follicular lymphoma].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same author

Liver Fibrosis Estimated Using Noninvasive Blood Biochemical Indices Is Correlated with Visit-to-Visit Glycated Hemoglobin A1c Variability in Individuals with Type 2 Diabetes.

Biomedicines·2026
Same author

Vaccine-Induced Anti-HBs Response is Associated with Protection Against Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Cell Transplantation: A Randomized Trial.

Transplantation and cellular therapy·2026
Same author

Congenital Factor XI deficiency in an elderly Japanese male accompanied by nonsense mutation p.Trp519* and novel missense mutation p.Ile618Phe.

The journal of medical investigation : JMI·2026
Same author

Selection of anti-CD38 antibodies for flow cytometric detection of myeloma cells treated with daratumumab or isatuximab.

International journal of hematology·2026

Related Experiment Video

Updated: Jun 25, 2026

Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology
08:01

Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology

Published on: March 22, 2012

27.9K

False-Positive Galactomannan Test Results in Multiple Myeloma.

Shingen Nakamura1, Yusaku Maeda2, Ryohei Sumitani2

  • 1Department of Community Medicine and Medical Science, Tokushima University Graduate School of Biomedical Sciences, Tokushima 7708503, Japan.

Diseases (Basel, Switzerland)
|April 25, 2025
PubMed
Summary

Serum galactomannan antigen (GM) tests are vital for diagnosing invasive pulmonary aspergillosis (IA) in hematological patients. However, results in multiple myeloma, especially IgG-type, may yield false positives, requiring cautious interpretation.

Keywords:
aspergillusgalactomannanmultiple myeloma

More Related Videos

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

15.7K
Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.1K

Related Experiment Videos

Last Updated: Jun 25, 2026

Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology
08:01

Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology

Published on: March 22, 2012

27.9K
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

15.7K
Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.1K

Area of Science:

  • Medical Mycology
  • Hematology
  • Infectious Diseases

Background:

  • Invasive pulmonary aspergillosis (IA) is a significant complication in patients with hematological diseases.
  • Early detection and treatment of IA are crucial for patient outcomes.
  • The serum galactomannan antigen (GM) test is a widely used diagnostic tool for IA, adhering to EORTC/MSG criteria.

Purpose of the Study:

  • To evaluate the diagnostic utility and potential for false positives of the serum galactomannan antigen (GM) test in patients with hematological diseases.
  • To investigate the positivity rates of GM tests across different hematological malignancies and immunoglobulin types.
  • To assess the implications of false-positive GM results in the context of IA diagnosis and management.

Main Methods:

  • Retrospective analysis of serum galactomannan antigen (GM) tests performed between April 2003 and January 2012.
  • Inclusion of 330 cases and 2155 samples in the analysis.
  • Evaluation of GM test results against the 2008 EORTC/MSG criteria for IA diagnosis.

Main Results:

  • Overall GM positivity rate was 25% (540/2155 samples).
  • Multiple myeloma (MM) showed the highest positivity rate (61.3%), with IgG-type MM having a 71.7% positivity rate.
  • Seventeen out of eighteen GM-positive MM cases were identified as false positives based on EORTC/MSG criteria.

Conclusions:

  • Serum galactomannan antigen (GM) testing in patients with hematological diseases, particularly IgG-type multiple myeloma, is prone to false-positive results.
  • These findings necessitate cautious interpretation of GM test results in specific patient populations.
  • Further investigation into subclinical IA and the impact of anti-myeloma treatments on GM values is warranted.